Determination of the yearly distribution of the incidence of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients registered in the cystic fibrosis patient registry system of Turkey and identification of risk factors for its development
Makaleler > Tam Makale · 2026
Yazarlar: Havva İpek Demir, Ebru Yalçın, Halime Nayır Büyükşahin, Suat Savaş, Velat Şen, Hadice Selimoğlu Şen, Azer Kılıç Başkan, Ayşe Ayzıt Kılınç, Hakan Yazan, Abdülhamit Çollak, Erkan Çakır, Hanife Tuğçe Çağlar, Fatih Ercan, Sevgi Pekcan, Merve Korkmaz, Yakup Canıtez, Bahar Girgin Dindar, Figen GÜLEN, Elif Arık, Özlem Keskin, Ali Ersoy, Mehmet Köse, Mahir Serbes, Derya Ufuk Altıntaş, Ebru Çelebioğlu, Oğuz Karcıoğlu, Abdurrahman Erdem Başaran, Ayşen Bingöl, Zeynep İlkşen Hocoğlu, Ayşe Tana Aslan, Demet Polat Yuluğ, Ali Özdemir, Işıl Bilgiç, Gökçen Dilşa Tuğcu, Koray Harmancı, Beste Özsezen, Pervin Korkmaz, Nazan Çobanoğlu, Hasan Yüksel, Sibel Doğru, Gönül Çaltepe, Melih Hangül, Zeynep Gökçe Gayretli Aydın, Mehmet Kılıç, Hamza Ogun, Mina Hızal, Ayşe Süleyman, Gizem Özcan, Aslı Görek Dilektaşlı, Tuğba Şişmanlar Eyüboğlu, Nagehan Emiralioğlu Ordukaya, Güzin Cinel, Uğur Özçelik, Deniz Doğru Ersöz
Chronic Illness, Uluslararası, Wos, 2026, cilt 22, ss 229-239
DOI: 10.1177/17423953261452631
Özet
Background Allergic bronchopulmonary aspergillosis (ABPA), is a hypersensitivity reaction in the lung against the antigens of Aspergillus fumigatus. The aim of this study is to determine the incidence of ABPA, and to determine the risk factors leading to the development of ABPA. Methods The study was designed as a retrospective cohort study. Using the CF Registry System of Turkey data, the incidence of ABPA was determined and the clinical and demographic characteristics of 44 patients newly diagnosed with ABPA in 2022 and 132 patients with similar mutation weight and age range without ABPA diagnosis in that year were examined and compared. Also risk factors affecting the development of ABPA were determined. Results Low pulmonary function test values, having had at least one pulmonary exacerbation in that year, receiving intravenous antibiotic treatment, using inhaled antibiotics, having high number of pulmonary exacerbations, having Pseudomonas aeruginosa colonization, having low body mass index (BMI), having cystic fibrosis related diabetes mellitus were found to be among the risk factors for the development of ABPA. Conclusions Early recognition and treatment of ABPA is essential to prevent further damage to the lungs. Patients with frequent pulmonary exacerbations, low BMI and low pulmonary function test values, chronic colonization should definitely be considered for ABPA.